7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow Protalix: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels PRX-115, Placebo - Gout | Phase 1 | Completed | Protalix | 64 | 2023-03-23 | 2025-02-11 |
| Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers AIR DNase, Placebo - Cystic Fibrosis (CF) | Phase 1 | Completed | Protalix | 18 | 2015-12-01 | 2016-05-17 |
| Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers OPRX-106 - Human Volunteer | Phase 1 | Completed | Protalix | 18 | 2014-07-01 | 2015-08-05 |
| Extension Study of PRX-102 for up to 60 Months PRX-102 (pegunigalsidase alfa) - Fabry Disease | Phase 1 / Phase 2 | Completed | Protalix | 15 | 2014-01-16 | 2023-09-13 |
| Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients PRX-112 - Gaucher Disease | Phase 1 | Completed | Protalix | 16 | 2013-03-01 | 2014-04-07 |
| Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients PRX-102 - Fabry Disease | Phase 1 / Phase 2 | Completed | Protalix | 18 | 2012-10-01 | 2023-09-13 |
| Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) Human Glucocerebrosidase (prGCD) - Gaucher Disease | Phase 1 | Completed | Protalix | 6 | 2005-11-01 | 2006-12-05 |
Fabry Disease (2) · Gaucher Disease (2) · Cystic Fibrosis (1) · Gout (1) · Hyperuricemia (1)
Etanercept (1) · taliglucerase alfa (1)
Israel (3) · Paraguay (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · New Zealand (1) · Serbia (1)
Einat Almon, PhD (2) · Einat Almon, PdH (1) · Eithan Galun, MD (1) · Mark Marshall, Dr. (1)